We have adopted the Triton platform across multiple facilities at Providence, and the integration of hemorrhage protocols and provider alerts will help us to deliver the best quality of maternal care, consistent with the Joint Commission’s new perinatal safety standard.

MENLO PARK, Calif. (PRWEB)
September 25, 2019

Gauss, the leader in AI-enabled surgical applications, announced an over-the-air software update, Triton QBL, that pairs the company’s AI-powered blood loss monitor with integrated protocols and provider alerts that help to synchronize postpartum hemorrhage care. The update will be available to the company’s network of hospital customers this fall.

The United States has the highest maternal mortality rate in the developed world (1). According to the Centers for Disease Control and Prevention (CDC), 60 percent of pregnancy-related deaths are preventable (2). Postpartum hemorrhage is the leading preventable cause of maternal morbidity and mortality (3), and obstetrics organizations such as the American College of Obstetrics and Gynecology (ACOG) and the California Maternal Quality Care Collaborative (CMQCC) recommend use of standardized hemorrhage management protocols (4,5).

On August 21, 2019, The Joint Commission, the body that accredits approximately 77 percent of hospitals in the United States, announced a perinatal safety guideline that requires accredited hospitals to “develop written, evidence-based procedures for stage-based management of pregnant and postpartum patients who experience maternal hemorrhage” incorporating “the use of an evidence-based tool that includes an algorithm for identification and treatment of hemorrhage.” (6) This new standard will go into effect July 1, 2020.

“Management of maternal hemorrhage with stage-based protocols based on cumulative, quantitative blood loss is imperative for safe obstetric care,” said David Lagrew, M.D., executive medical director of Women’s Services at Providence St. Joseph’s Health and co-chair of the CMQCC Maternal Quality Care Collaborative’s Hemorrhage Task Force. “We have adopted the Triton platform across multiple facilities at Providence, and the integration of hemorrhage protocols and provider alerts will help us to deliver the best quality of maternal care, consistent with the Joint Commission’s new perinatal safety standard.”

Triton is the only FDA-cleared and CE Marked system for blood loss monitoring in surgery and obstetrics. It leverages computer vision and the CoreML capability of the iPad and iPhone to monitor blood loss from images captured by the TrueDepth sensor. Triton adoption has grown by more than 100 percent year-over-year, and Gauss’s U.S. customers perform approximately 250,000 deliveries per year (7). Researchers at Mount Sinai Hospital in New York recently published an independent 7,600 patient study in the International Journal of Obstetric Anesthesia on the use of Triton to power a stage-based hemorrhage protocol. The use of Triton was associated with a 340 percent increase in hemorrhage recognition, a 34 percent reduction in delayed interventions to control bleeding in vaginal deliveries, reduced transfusion dose in Caesarean sections, and cost savings leading to a 152 percent return on investment (8).

Triton QBL is compatible with both iPhone and iPad platforms and enables hospitals to embed their own hemorrhage protocols and set customized alerts based on quantified blood loss (QBL) thresholds, delivering real-time guidance to clinicians and facilitating communication and rapid response during an emerging hemorrhage. U.S. hospitals are rapidly adopting smartphones to improve communication and collaboration among clinical teams (9), and Triton’s new iPhone compatibility delivers a mobile platform that enables health systems to leverage their IT investment in enterprise-issued phones.

“We are incredibly excited about this significant evolution of the Triton system to power hemorrhage protocols and support better maternal care,” said Siddarth Satish, founder and chief executive officer of Gauss. “With hundreds of thousands of enterprise-issued iPhones in use by clinical staff in hospitals today, these latest developments enable us to extend the benefits of our AI-enabled patient safety platform to many more patients and healthcare providers.”

About Gauss

Gauss is transforming surgery with an AI-enabled mobile platform for the operating room. Based in Silicon Valley, the company leverages computer vision, machine learning, and artificial intelligence to power surgical safety protocols by delivering real-time insights, simplifying clinical workflow, and closing communication gaps. The company’s flagship Triton platform is FDA cleared and CE Marked and powers maternal hemorrhage protocols in hospitals performing over 250,000 annual deliveries. Triton received the 2018 Apple Design Award, which recognizes the best in design, innovation and technology on Apple platforms. For more information, visit http://www.gauss.com.

(1) Kassebaum NJ, Barber RM, Bhutta ZA, et al; GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1775-1812.

(2) Petersen EE, Davis NL, Goodman D, Cox S, Mayes N, Johnston E, et al. Vital signs: pregnancy-related deaths, United States, 2011-2015, and strategies for prevention, 13 states, 2013-2017. MMWR Morb Mortal Wkly Rep 2019;68:423–9.

(3) Ibid.

(4) https://www.acog.org/About-ACOG/News-Room/News-Releases/2017/ACOG-Expands-Recommendations-to-Treat-Postpartum-Hemorrhage?

(5) https://www.cmqcc.org/resources-tool-kits/toolkits/ob-hemorrhage-toolkit

(6) https://www.jointcommission.org/assets/1/6/New_Perinatal_Standards_Prepub_Report.pdf

(7) American Hospital Association Data and Gauss Internal Estimates

(8) Katz D, Wang R, O’Neil L, Gerber C, Lankford A, Rogers T, Gal J, Sandler R, Beilin Y., et al. The association between the introduction of quantitative assessment of postpartum blood loss and institutional changes in clinical practice: an observational study. Int J Obstet Anesth. 2019 May 13. pii: S0959-289X(19)30070-6. doi: 10.1016/j.ijoa.2019.05.006. [Epub ahead of print]

(9) https://www.beckershospitalreview.com/healthcare-information-technology/survey-90-of-hospitals-investing-in-smartphones-for-clinical-communication.html

Share article on social media or email:

Stuart Long, CEO of InfoBionic, underscores how to increase patient compliance with cardiac monitoring.

“Remote patient monitoring not only gives people convenient access to their healthcare provider, but also a tangible connection to their own health.”

WALTHAM, Mass. (PRWEB)
September 25, 2019

Lack of patient compliance is a well-known source of frustration for physicians, particularly when it comes to people with chronic health conditions. Remote patient monitoring (RPM) can lead to greater patient engagement, which in turn can elevate compliance with physician recommendations, including taking medications as prescribed and making important lifestyle changes, said InfoBionic CEO Stuart Long.

While it’s counterproductive to ignore what physicians advise us, well-established human behavior has proven that we don’t always do what’s best for us. Not only that, patients who are only told what to do are less engaged and compliant than those who can see positive changes from following physician instructions, said Long, whose Massachusetts-based company makes a non-invasive, full-disclosure remote cardiac monitor.

Some healthcare experts call medical noncompliance a national epidemic [1].

“Patient engagement happens when patients take ownership of their health,” Long said. “Remote patient monitoring not only gives people convenient access to their healthcare provider, but also a tangible connection to their own health. That has a significant impact on engagement and compliance.”

It also can reduce healthcare costs. Eighty-six percent of healthcare costs are for people with chronic conditions, including diabetes, obesity, cardiovascular disease and dementia, according to data published in 2017 in the American Journal of Preventive Medicine [2]. A 2015 study in American Journal of Managed Care found that people who received the most healthcare, especially patients with more than one chronic condition, were five times more likely to need emergency department services [3].

Philadelphia cardiologist Colin Movsowitz, M.D. said that patients are far more likely to correctly wear a remote monitor when its operation is easy to understand, and it is simple and convenient to wear. This is especially important with older patients who may not be tech savvy, he said.

“The value of easy-to-use remote cardiac monitoring is tremendous,” Dr. Movsowitz said. “Not only because of the clinical data that we wouldn’t get any other way, but also because of the increased level of patient engagement, compliance and satisfaction.”

Patients, especially younger ones, want to use RPM and other telemedicine technology, according to Accenture’s 2019 Digital Health Consumer Survey, which found that 53 percent of patients surveyed said they are more likely to choose a primary care provider who uses remote or telemonitoring devices [4]. A 2018 survey by Black Book found that 84 percent of patients want providers who use technology that helps them communicate with their doctors and engage with their own health data [5].

In 2016, seven million people were using remote monitoring and other internet-connected medical devices, according to a report by Berg Insight. By 2021, that number is expected to increase to more than 50 million [6].

About InfoBionic

InfoBionic is a digital health company transforming the efficiency and economics of ambulatory remote patient monitoring processes by optimizing clinical and real-world utility for the users that need it most – physicians and their patients. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices and mobile technology, and bring specific expertise in remote monitoring and cardiology. They have seen first-hand the complexities of traditional cardiac arrhythmia detection and monitoring processes and designed the transformative MoMe® Kardia platform to remove the roadblocks hindering faster, more effective diagnosis and decision-making. Frost & Sullivan bestowed the 2019 North American Remote Cardiac Monitoring Technology Leadership Award upon InfoBionic. For more information visit http://www.infobionic.com

About MoMe® Kardia

The company’s flagship product, the MoMe® Kardia 3-in1 monitor, is the first non-invasive remote cardiac monitor to offer truly full disclosure, heartbeat-to-heartbeat data over the Cloud, allowing doctors 24/7 real-time access to hospital telemetry-level data. With the MoMe® Kardia, doctors will be able to eliminate third-party monitoring data services and take full ownership of the cardiac monitoring process, empowering them to realize lucrative new revenue streams by billing globally for the monitoring service. MoMe® Kardia is not intended for use as an emergency medical response system. Call 911 if you feel you are having a medical emergency.

1. Scarlett, William, and Steve Young. “Medical Noncompliance: The Most Ignored National Epidemic.” The Journal of the American Osteopathic Association, American Osteopathic Association, 1 Aug. 2016.

2. Chapel, John M, et al. “Prevalence and Medical Costs of Chronic Diseases Among Adult Medicaid Beneficiaries.” American Journal of Preventive Medicine, U.S. National Library of Medicine, Dec. 2017.

3. Owens, Gary. “Economic Burden of Multiple Sclerosis and the Role of Managed Care Organizations in Multiple Sclerosis Management.” AJMC, 31 May 2016.

4. Safavi, Kaveh. “Today’s Consumers Reveal the Future of Healthcare.” Accenture.

5. Research, Black Book. “Hospital Technology Is the New Determiner of Patient Satisfaction, 2018 Black Book EHR User Survey Results.” PR Newswire: Press Release Distribution, Targeting, Monitoring and Marketing, 27 June 2018.

6. Insight, Berg. MHealth and Home Monitoring.

Share article on social media or email: